STOCK TITAN

[8-K] Sensei Biotherapeutics, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Sensei Biotherapeutics, Inc. (SNSE) announced, via an Item 3.01 Form 8-K, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Nasdaq Listing Qualifications Staff confirmed that SNSE’s common stock maintained a closing bid of at least $1.00 for ten consecutive business days (17 June – 1 July 2025). As a result, the prior deficiency notice has been closed and the threat of delisting has been removed.

This resolution eliminates near-term listing risk, restores eligibility for index inclusion and institutional ownership mandates tied to national exchange status, and reduces investor concern over potential liquidity constraints. However, compliance depends on SNSE’s ability to keep its share price above the threshold; any sustained drop below $1.00 could trigger a new notice. The filing contains no new operational or financial data and does not alter the company’s underlying fundamentals.

Sensei Biotherapeutics, Inc. (SNSE) ha annunciato, tramite un modulo 8-K, Item 3.01, di aver ritrovato la conformità con la regola di quotazione Nasdaq 5550(a)(2), che richiede un prezzo minimo di offerta di $1,00 per azione. Lo staff delle qualifiche di quotazione Nasdaq ha confermato che le azioni ordinarie di SNSE hanno mantenuto un prezzo di chiusura di almeno $1,00 per dieci giorni lavorativi consecutivi (dal 17 giugno al 1 luglio 2025). Di conseguenza, la precedente comunicazione di non conformità è stata chiusa e il rischio di esclusione dalla quotazione è stato eliminato.

Questa risoluzione elimina il rischio di esclusione a breve termine, ripristina l'idoneità per l'inclusione negli indici e per i mandati di proprietà istituzionale legati allo status di borsa nazionale, e riduce le preoccupazioni degli investitori riguardo a potenziali problemi di liquidità. Tuttavia, la conformità dipende dalla capacità di SNSE di mantenere il prezzo delle azioni sopra la soglia; un calo prolungato sotto $1,00 potrebbe generare una nuova comunicazione. Il documento non contiene nuovi dati operativi o finanziari e non modifica i fondamenti aziendali sottostanti.

Sensei Biotherapeutics, Inc. (SNSE) anunció, a través de un Formulario 8-K, Ítem 3.01, que ha recuperado el cumplimiento con la Regla de Cotización Nasdaq 5550(a)(2), la cual requiere un precio mínimo de oferta de $1.00 por acción. El personal de Calificaciones de Cotización de Nasdaq confirmó que las acciones comunes de SNSE mantuvieron un precio de cierre de al menos $1.00 durante diez días hábiles consecutivos (del 17 de junio al 1 de julio de 2025). Como resultado, la notificación previa de incumplimiento ha sido cerrada y se ha eliminado la amenaza de exclusión.

Esta resolución elimina el riesgo de exclusión a corto plazo, restaura la elegibilidad para la inclusión en índices y mandatos de propiedad institucional vinculados al estatus de bolsa nacional, y reduce la preocupación de los inversores sobre posibles limitaciones de liquidez. Sin embargo, el cumplimiento depende de la capacidad de SNSE para mantener su precio por encima del umbral; cualquier caída sostenida por debajo de $1.00 podría desencadenar una nueva notificación. El documento no contiene datos operativos o financieros nuevos y no altera los fundamentos subyacentes de la empresa.

Sensei Biotherapeutics, Inc. (SNSE)는 Item 3.01 Form 8-K를 통해 Nasdaq 상장 규정 5550(a)(2)의 준수를 회복했다고 발표했습니다. 이 규정은 주당 최소 입찰가 $1.00을 요구합니다. Nasdaq 상장 자격 담당자는 SNSE의 보통주가 2025년 6월 17일부터 7월 1일까지 10거래일 연속으로 $1.00 이상의 종가를 유지했다고 확인했습니다. 그 결과, 이전의 불이행 통지는 종료되었으며 상장 폐지 위협도 해소되었습니다.

이번 해결로 단기 상장 위험이 사라지고, 지수 편입 자격과 국가 거래소 지위와 연계된 기관 투자자 보유 요건이 복원되었으며, 투자자들의 유동성 문제 우려도 줄어들었습니다. 다만, 준수 여부는 SNSE가 주가를 기준선 이상으로 유지할 수 있는지에 달려 있으며, $1.00 미만으로 장기간 하락할 경우 새로운 통지가 발생할 수 있습니다. 이번 제출 서류에는 새로운 운영 또는 재무 데이터가 포함되어 있지 않으며, 회사의 기본적인 펀더멘털에는 변화가 없습니다.

Sensei Biotherapeutics, Inc. (SNSE) a annoncé, via un formulaire 8-K, Item 3.01, qu'elle a retrouvé la conformité avec la règle de cotation Nasdaq 5550(a)(2), qui exige un prix d'offre minimum de 1,00 $ par action. Le personnel des qualifications de cotation Nasdaq a confirmé que les actions ordinaires de SNSE ont maintenu un cours de clôture d'au moins 1,00 $ pendant dix jours ouvrables consécutifs (du 17 juin au 1er juillet 2025). En conséquence, la notification de non-conformité précédente a été clôturée et la menace de radiation a été levée.

Cette résolution élimine le risque de radiation à court terme, restaure l'éligibilité à l'inclusion dans les indices et aux mandats de détention institutionnelle liés au statut d'échange national, et réduit les inquiétudes des investisseurs concernant d'éventuelles contraintes de liquidité. Cependant, la conformité dépend de la capacité de SNSE à maintenir son cours au-dessus du seuil ; toute baisse prolongée sous 1,00 $ pourrait entraîner une nouvelle notification. Le dépôt ne contient aucune nouvelle donnée opérationnelle ou financière et ne modifie pas les fondamentaux sous-jacents de l'entreprise.

Sensei Biotherapeutics, Inc. (SNSE) gab über ein Item 3.01 Form 8-K bekannt, dass das Unternehmen die Einhalten der Nasdaq-Listing-Regel 5550(a)(2) wiedererlangt hat, welche einen Mindestgebotspreis von 1,00 $ pro Aktie vorschreibt. Das Nasdaq Listing Qualifications Team bestätigte, dass die Stammaktien von SNSE für zehn aufeinanderfolgende Handelstage (17. Juni bis 1. Juli 2025) einen Schlusskurs von mindestens 1,00 $ aufwiesen. Infolgedessen wurde die vorherige Mängelmitteilung geschlossen und die Gefahr eines Delistings beseitigt.

Diese Lösung beseitigt das kurzfristige Listing-Risiko, stellt die Berechtigung für die Aufnahme in Indizes und institutionelle Besitzvorgaben im Zusammenhang mit dem Status an einer nationalen Börse wieder her und verringert die Besorgnis der Investoren über mögliche Liquiditätsengpässe. Die Einhaltung hängt jedoch davon ab, dass SNSE den Aktienkurs über der Schwelle hält; ein anhaltender Rückgang unter 1,00 $ könnte eine neue Mitteilung auslösen. Die Einreichung enthält keine neuen operativen oder finanziellen Daten und ändert nicht die zugrunde liegenden Fundamentaldaten des Unternehmens.

Positive
  • Regained Nasdaq compliance under Rule 5550(a)(2), removing imminent delisting risk.
  • Improved liquidity and investor perception by maintaining national exchange status.
Negative
  • Share-price fragility remains; any fall below $1.00 could renew deficiency.
  • Event does not address operational fundamentals or cash needs.

Insights

TL;DR: Nasdaq closes delisting threat; liquidity and investor confidence improve, but price must stay above $1.

The lift of the bid-price deficiency is materially positive for SNSE as it removes a technical overhang that can suppress trading volumes and deter institutional holders. Retention of Nasdaq listing preserves access to capital markets and potential inclusion in small-cap indices. The event does not address core clinical or cash-runway challenges; share price stability remains the key variable. Overall, the action is modestly accretive to sentiment rather than fundamentals.

TL;DR: Compliance restored, governance risk lowered; vigilance required to prevent future bid-price breaches.

Regained compliance signals effective board oversight in resolving exchange deficiencies, minimizing reputational and governance risk. Continued adherence will require proactive investor-relations outreach and potential corporate actions (reverse split, capital raise) if market pressure resurfaces. No changes to control structure or reporting obligations were disclosed.

Sensei Biotherapeutics, Inc. (SNSE) ha annunciato, tramite un modulo 8-K, Item 3.01, di aver ritrovato la conformità con la regola di quotazione Nasdaq 5550(a)(2), che richiede un prezzo minimo di offerta di $1,00 per azione. Lo staff delle qualifiche di quotazione Nasdaq ha confermato che le azioni ordinarie di SNSE hanno mantenuto un prezzo di chiusura di almeno $1,00 per dieci giorni lavorativi consecutivi (dal 17 giugno al 1 luglio 2025). Di conseguenza, la precedente comunicazione di non conformità è stata chiusa e il rischio di esclusione dalla quotazione è stato eliminato.

Questa risoluzione elimina il rischio di esclusione a breve termine, ripristina l'idoneità per l'inclusione negli indici e per i mandati di proprietà istituzionale legati allo status di borsa nazionale, e riduce le preoccupazioni degli investitori riguardo a potenziali problemi di liquidità. Tuttavia, la conformità dipende dalla capacità di SNSE di mantenere il prezzo delle azioni sopra la soglia; un calo prolungato sotto $1,00 potrebbe generare una nuova comunicazione. Il documento non contiene nuovi dati operativi o finanziari e non modifica i fondamenti aziendali sottostanti.

Sensei Biotherapeutics, Inc. (SNSE) anunció, a través de un Formulario 8-K, Ítem 3.01, que ha recuperado el cumplimiento con la Regla de Cotización Nasdaq 5550(a)(2), la cual requiere un precio mínimo de oferta de $1.00 por acción. El personal de Calificaciones de Cotización de Nasdaq confirmó que las acciones comunes de SNSE mantuvieron un precio de cierre de al menos $1.00 durante diez días hábiles consecutivos (del 17 de junio al 1 de julio de 2025). Como resultado, la notificación previa de incumplimiento ha sido cerrada y se ha eliminado la amenaza de exclusión.

Esta resolución elimina el riesgo de exclusión a corto plazo, restaura la elegibilidad para la inclusión en índices y mandatos de propiedad institucional vinculados al estatus de bolsa nacional, y reduce la preocupación de los inversores sobre posibles limitaciones de liquidez. Sin embargo, el cumplimiento depende de la capacidad de SNSE para mantener su precio por encima del umbral; cualquier caída sostenida por debajo de $1.00 podría desencadenar una nueva notificación. El documento no contiene datos operativos o financieros nuevos y no altera los fundamentos subyacentes de la empresa.

Sensei Biotherapeutics, Inc. (SNSE)는 Item 3.01 Form 8-K를 통해 Nasdaq 상장 규정 5550(a)(2)의 준수를 회복했다고 발표했습니다. 이 규정은 주당 최소 입찰가 $1.00을 요구합니다. Nasdaq 상장 자격 담당자는 SNSE의 보통주가 2025년 6월 17일부터 7월 1일까지 10거래일 연속으로 $1.00 이상의 종가를 유지했다고 확인했습니다. 그 결과, 이전의 불이행 통지는 종료되었으며 상장 폐지 위협도 해소되었습니다.

이번 해결로 단기 상장 위험이 사라지고, 지수 편입 자격과 국가 거래소 지위와 연계된 기관 투자자 보유 요건이 복원되었으며, 투자자들의 유동성 문제 우려도 줄어들었습니다. 다만, 준수 여부는 SNSE가 주가를 기준선 이상으로 유지할 수 있는지에 달려 있으며, $1.00 미만으로 장기간 하락할 경우 새로운 통지가 발생할 수 있습니다. 이번 제출 서류에는 새로운 운영 또는 재무 데이터가 포함되어 있지 않으며, 회사의 기본적인 펀더멘털에는 변화가 없습니다.

Sensei Biotherapeutics, Inc. (SNSE) a annoncé, via un formulaire 8-K, Item 3.01, qu'elle a retrouvé la conformité avec la règle de cotation Nasdaq 5550(a)(2), qui exige un prix d'offre minimum de 1,00 $ par action. Le personnel des qualifications de cotation Nasdaq a confirmé que les actions ordinaires de SNSE ont maintenu un cours de clôture d'au moins 1,00 $ pendant dix jours ouvrables consécutifs (du 17 juin au 1er juillet 2025). En conséquence, la notification de non-conformité précédente a été clôturée et la menace de radiation a été levée.

Cette résolution élimine le risque de radiation à court terme, restaure l'éligibilité à l'inclusion dans les indices et aux mandats de détention institutionnelle liés au statut d'échange national, et réduit les inquiétudes des investisseurs concernant d'éventuelles contraintes de liquidité. Cependant, la conformité dépend de la capacité de SNSE à maintenir son cours au-dessus du seuil ; toute baisse prolongée sous 1,00 $ pourrait entraîner une nouvelle notification. Le dépôt ne contient aucune nouvelle donnée opérationnelle ou financière et ne modifie pas les fondamentaux sous-jacents de l'entreprise.

Sensei Biotherapeutics, Inc. (SNSE) gab über ein Item 3.01 Form 8-K bekannt, dass das Unternehmen die Einhalten der Nasdaq-Listing-Regel 5550(a)(2) wiedererlangt hat, welche einen Mindestgebotspreis von 1,00 $ pro Aktie vorschreibt. Das Nasdaq Listing Qualifications Team bestätigte, dass die Stammaktien von SNSE für zehn aufeinanderfolgende Handelstage (17. Juni bis 1. Juli 2025) einen Schlusskurs von mindestens 1,00 $ aufwiesen. Infolgedessen wurde die vorherige Mängelmitteilung geschlossen und die Gefahr eines Delistings beseitigt.

Diese Lösung beseitigt das kurzfristige Listing-Risiko, stellt die Berechtigung für die Aufnahme in Indizes und institutionelle Besitzvorgaben im Zusammenhang mit dem Status an einer nationalen Börse wieder her und verringert die Besorgnis der Investoren über mögliche Liquiditätsengpässe. Die Einhaltung hängt jedoch davon ab, dass SNSE den Aktienkurs über der Schwelle hält; ein anhaltender Rückgang unter 1,00 $ könnte eine neue Mitteilung auslösen. Die Einreichung enthält keine neuen operativen oder finanziellen Daten und ändert nicht die zugrunde liegenden Fundamentaldaten des Unternehmens.

false 0001829802 0001829802 2025-07-02 2025-07-02
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 2, 2025

 

 

Sensei Biotherapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-39980   83-1863385

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

1405 Research Blvd, Suite 125

Rockville, MD

  20850
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (240) 243-8000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class

 

Trading

symbol

 

Name of each exchange

on which registered

Common Stock   SNSE   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 
 


Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On July 2, 2025, Sensei Biotherapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined that for 10 consecutive business days, from June 17, 2025 to July 1, 2025, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Staff has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2).

 

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Sensei Biotherapeutics, Inc.
Date: July 9, 2025      

/s/ Christopher W. Gerry

      Christopher W. Gerry
      General Counsel and Secretary

 

3

FAQ

Why did Sensei Biotherapeutics (SNSE) file this Form 8-K?

To disclose that Nasdaq confirmed SNSE has regained compliance with the $1.00 minimum bid-price rule.

What is Nasdaq Listing Rule 5550(a)(2)?

It requires a company’s common stock to maintain a minimum closing bid price of $1.00 for continued listing on the Nasdaq Capital Market.

How did SNSE regain compliance?

SNSE’s shares closed at or above $1.00 for 10 consecutive business days (17 Jun–1 Jul 2025), satisfying Nasdaq’s cure criteria.

Does this filing affect SNSE’s financial outlook?

No financial metrics were disclosed; the filing solely addresses listing status, not operational performance.

Could SNSE face delisting again?

Yes. If the bid price falls below $1.00 for 30 consecutive business days, Nasdaq may issue a new deficiency notice.
Sensei Biotherapeutics, Inc.

NASDAQ:SNSE

SNSE Rankings

SNSE Latest News

SNSE Stock Data

11.38M
829.83k
34.22%
9.37%
0.58%
Biotechnology
Pharmaceutical Preparations
Link
United States
ROCKVILLE